Comparing the efficacy of Molnupiravir and placebo on recovery rate in patients with mild COVID-19, a randomized multicenter clinical trial

Bagheiat-allah University of Medical Sciences0 个研究点目标入组 500 人开始时间: 待定最近更新: 2022年8月29日

试验速览

暂无简介。

•Living in a family with at least one infected person with COVID-19
•Not having pulmonary involvement
•Not having symptoms like chest wall pain and dysnea suggesting pulmonary involvement
•Positive PCR test of COVID-19
•Patient with COVID-19 symptoms lesser than 3 days
•Patients satisfied with consumption of oral medication
•Blood oxygen saturation above 93 percents

•Patients under 18 years old
•Having underlying diseases such as uncontrolled diabetes, uncontrolled blood pressure, liver and heart disease and kidney, heart and liver failure
•History of any of the diseases including hepatitis B or C, HIV, autoimmune diseases and immunodeficiency
•History of hepatocellular disease, liver failure and heart failure of liver tests more than 3 times normal
•History of allergy to antiviral drugs
•Existence of thrombocytopenia (platelets under 100000)
•History of recent COVID-19 vaccination lesser than 7 days
•being pregnant
•breastfeeding

发起方

Bagheiat-allah University of Medical Sciences